Myriad Genetics Inc
MYGN
MYGN: Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
moreShow MYGN Financials
Recent trades of MYGN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MYGN's directors and management
Government lobbying spending instances
-
$210,000 Jul 17, 2023 Issue: Health Issues Medicare/Medicaid Budget/Appropriations
-
$390,000 Apr 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations
-
$290,000 Jan 20, 2023 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$210,000 Oct 19, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$180,000 Jul 20, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$290,000 Apr 20, 2022 Issue: Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$200,000 Jan 20, 2022 Issue: None
-
$160,000 Oct 20, 2021 Issue: None
-
$170,000 Jul 20, 2021 Issue: None
-
$240,000 Apr 20, 2021 Issue: None
-
$210,000 Jan 20, 2021 Issue: None
-
$156,000 Oct 20, 2020 Issue: None
-
$130,000 Jul 20, 2020 Issue: None
-
$220,000 Apr 20, 2020 Issue: None
-
$240,000 Jan 21, 2020 Issue: None
-
$260,000 Oct 21, 2019 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues Budget/Appropriations
-
$170,000 Jul 22, 2019 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$240,000 Apr 22, 2019 Issue: Medical/Disease Research/Clinical Labs Copyright/Patent/Trademark Medicare/Medicaid
-
$230,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Copyright/Patent/Trademark
-
$60,000 Oct 18, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Veterans
New patents grants
Federal grants, loans, and purchases
- $74,970 2022-08-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $3,900 2022-03-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $29,920 2020-11-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $50,000 2020-09-30 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $35,904 2018-11-26 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $100,000 2018-07-12 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
Followers on MYGN's company Twitter account
Number of mentions of MYGN in WallStreetBets Daily Discussion
Recent insights relating to MYGN
Recent picks made for MYGN stock on CNBC
ETFs with the largest estimated holdings in MYGN
Flights by private jets registered to MYGN